REVIEWED RESEARCH DIGEST / DIRECT ANSWERS
BPC-157 FAQ: the common questions, answered from the record
Twenty-five questions about BPC-157 mechanism, safety, timeline, administration, and access — each answered directly, graded for confidence, and cited where it makes a quantitative claim.
How does BPC-157 work?
In animal and cell models, BPC-157's repair effects are most consistently linked to angiogenesis: it up-regulates and internalizes the VEGFR2 receptor, driving downstream VEGFR2-Akt-eNOS (nitric-oxide) signaling [3]. Additional reported routes include the nitric-oxide system and the FAK-paxillin pathway. These are preclinical mechanisms, not established human pharmacology.
What is BPC-157's mechanism of action?
The best-characterized pathway is pro-angiogenic VEGFR2 activation and up-regulation feeding the Akt-eNOS axis [3]. It is proposed as a unifying mechanism that ties together BPC-157's reported tissue-repair, vascular, and cytoprotective effects across rodent models. The VEGFR2-Akt-eNOS pathway is covered in full on the angiogenesis page.
What does BPC-157 do in the body?
In animal studies it is described as a cytoprotective peptide that promotes new blood-vessel formation and accelerates healing of tissues such as gastric ulcers [4] and transected tendon [1]. Human evidence is limited to a few small pilot studies, so what it does 'in the body' is characterized mainly in rodents [12].
Does BPC-157 cause cancer?
There is no published evidence that BPC-157 causes cancer. Because one proposed mechanism is pro-angiogenic VEGFR2 activation [3], a theoretical question about tumor vascularization is reasonable, but it has not been studied, and the 2025 reviews treating BPC-157 as investigational report no carcinogenicity data either way [12].
Does BPC-157 lower blood pressure?
There is no human blood-pressure data. In rodent models BPC-157 prevented and reversed monocrotaline-induced pulmonary hypertension, a lung-vessel pressure model [7], and it modulates vasomotor tone through the nitric-oxide system. These are animal vascular findings, not a demonstrated blood-pressure effect in people.
Does BPC-157 raise blood pressure?
No human data show that it raises blood pressure. Its reported vascular activity in animals centers on nitric-oxide and VEGFR2 signaling, generally vasodilatory in direction [3], and a 2025 human IV safety pilot reported no measurable cardiac biomarker changes [11] — though it involved only two people.
Can BPC-157 help heal burns or skin wounds?
In rats, BPC-157 accelerated alkali-burn wound healing, and in cell culture it promoted proliferation, migration, and angiogenesis [8]. This is animal and in-vitro wound-healing evidence; there is no controlled human burn or wound study, so it is graded ESTABLISHED in animals and NO HUMAN DATA in people.
Is BPC-157 a growth hormone?
No. BPC-157 is a synthetic 15-amino-acid peptide derived from a fragment of a gastric protein, not a growth hormone. Some tendon studies report it can sensitize cells to growth-hormone signaling, but the molecule itself is not a hormone and is rapidly broken down into ordinary peptide fragments [2].
Does BPC-157 work immediately?
No. Even in the most-cited animal model, tendon healing improved progressively over days of once-daily dosing [1], and the peptide itself clears quickly, with an elimination half-life under 30 minutes in animals [2]. An 'immediate' effect claim is not supported by the research.
Does BPC-157 damage the liver?
Published animal work points the other way: BPC-157 reduced bile-duct-ligation liver injury in rats [9] and lowered distant-organ liver damage in a rat acute-pancreatitis model [14]. A 2025 human IV pilot reported no measurable hepatic biomarker changes [11], but with only two participants the human liver-safety picture is essentially unknown.
Is BPC-157 hard on the kidneys?
No published study reports kidney harm; one 2025 rat study found BPC-157 reduced kidney, liver, and lung distant-organ damage in acute pancreatitis [14]. The 2025 human IV safety pilot reported no measurable renal biomarker changes [11], but in only two people, so human renal safety is not established.
Can BPC-157 mess with your heart?
In rodents the cardiac literature is protective rather than harmful: BPC-157 attenuated isoprenaline-induced myocardial infarction [5] and is reviewed as cytoprotective in heart-disturbance models [6]. A 2025 two-person IV pilot reported no measurable cardiac biomarker changes [11]. Human cardiac safety remains unproven at scale.
Is BPC-157 bad for the heart?
There is no evidence it is bad for the heart. Animal models show cardioprotective signals, including reduced myocardial-infarction injury [5], and the small human IV pilot reported no adverse cardiac findings [11]. As with every BPC-157 question, the human dataset is tiny [12].
Can BPC-157 cause liver damage?
Published evidence does not show liver damage; rat studies report hepatoprotection in bile-duct ligation [9] and acute-pancreatitis distant-organ protection [14], and a human IV pilot found no hepatic biomarker changes [11]. Long-term human liver-safety data simply do not exist yet [12].
How long should I stay on BPC-157?
There is no validated human duration. Research doses are expressed per body weight in animals, often around 10 microg/kg [1], and the only human exposures are single-session or two-day pilot protocols [11]. No study establishes a safe or effective human course length, and how BPC-157 doses are expressed is covered on the dosage page.
What happens when you stop taking BPC-157?
No withdrawal or rebound effect has been studied in humans. Pharmacokinetically the peptide clears quickly, with an elimination half-life under 30 minutes in animals and rapid breakdown into ordinary amino-acid fragments [2], so it does not accumulate.
What should you not mix with BPC-157?
There are no human drug-interaction studies, so no interaction profile is established at all. The honest answer from the literature is that combinations in people are simply unknown, because the evidence base is overwhelmingly preclinical and the human dataset is three small pilots [12]. This digest grades the interaction question NO HUMAN DATA rather than guessing at a safe-to-combine list.
Can BPC-157 heal arthritis?
No controlled trial shows it heals arthritis. A small uncontrolled human case series reported reduced knee pain across several pain types after intra-articular BPC-157 injection [10], but with no comparator group and no imaging endpoint, a case series cannot separate a real effect from placebo or natural recovery. It is graded PILOT-ONLY, which is not the same as evidence of healing.
How does BPC-157 make you feel?
There is no validated human experiential data. The 2025 narrative review stresses that human evidence is limited to three small pilot studies and that BPC-157 should be treated as investigational [12], so subjective-effect claims are anecdotal, not research-backed.
How long does BPC-157 take to work?
Animal healing timelines run over days to weeks: in the transected-tendon model, recovery improved progressively across repeated daily dosing rather than after a single dose [1]. No human timeline is established, and the peptide itself is short-lived in circulation, clearing with a half-life under 30 minutes [2], so any reported tissue effect reflects a slow repair process, not a fast drug action.
How long does it take for BPC-157 to kick in?
Research does not define a human onset. Effects in animal repair models accrue over repeated dosing rather than instantly, and the molecule clears within minutes, with a half-life under 30 minutes [2], so reported tissue effects reflect a biological healing process, not an acute drug 'hit'.
Can BPC-157 be taken orally?
It is termed a 'stable gastric pentadecapeptide' because it is reported stable in gastric juice, and animal ulcer work used intragastric dosing, with intramuscular outperforming it [4]. Despite this, formal human oral pharmacokinetics are not established, so oral efficacy in people is unproven.
Is BPC-157 legal?
BPC-157 is not an FDA-approved drug, and as of the latest confirmable FDA action it sits in 503A Category 2 — bulk substances FDA identified as potentially raising significant safety risks, not within FDA's enforcement-discretion policy for compounding [16]. It is also prohibited in sport at all times by WADA. See the BPC-157 FDA 503A compounding status page for the full record.
Can you get BPC-157 from a compounding pharmacy?
Compounding access turns on ingredient eligibility. A 503A pharmacy may use a bulk substance only if it is on FDA's bulks list, has a USP/NF monograph, or is a component of an approved drug; a substance FDA flagged for significant safety risks is not eligible for routine 503A compounding while that status stands [18]. BPC-157's Category 2 status [16] is the gating fact today, detailed on the BPC-157 legal status and 503A category page.
What is the FDA 503A status of BPC-157?
BPC-157 ('BPC-157 (free base)' and 'BPC-157 acetate') was placed in 503A Category 2, effective with FDA's September 29, 2023 nominated-substances update, citing concerns including potential immunogenicity for certain routes and peptide impurity and characterization complexity [16]. It is individually named on the July 23-24, 2026 PCAC agenda as a substance being considered for the 503A Bulks List — a scheduled evaluation only, not a decision [17].